louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02245607: Compensatory Cognitive Training in Clinical High Risk Latino Youth
Official title: Compensatory Cognitive Training in Clinical High Risk Latino Youth
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Clinical High Risk
Psychosis
Prodromal
Schizophrenia
Keywords: Psychotic Disorders
Cognitive Training
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2014-09-19
Enrollment: 120
Sex: ALL
Minimum age (years): 12
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized study to compare Compensatory Cognitive Training (CCT) versus Recreational Therapy (RT) in Latino clinical high risk individuals in the US and Mexico.

Study hypotheses: Compared to those who receive RT, study participants receiving CCT will show significant improvement in neurocognition, functional capacity, self-rated functioning and clinical measures.

Detailed description: This is a 12 week randomized study to compare Compensatory Cognitive Training (CCT) versus Recreational Therapy (RT) in Latino clinical high risk individuals in the US and Mexico.

Study participants will be measured 3 times, at baseline, 12 and 24 weeks on all outcome measures. Study hypothesis: Study participants receiving CCT will show significant improvement at 12 and 24 weeks compared to baseline in 1) Neurocognition using the Global Cognitive Index z score derived from the MATRICS neurocognitive domain scores, 2) Functional Capacity as assessed by the UCSD Performance-based Skills Assessment (UPSA/UPSA-Adolescent), 3) Self-Rated Functioning as measured by the Specific Level of Functioning Scale (SLoF) and 4) Clinical symptom ratings as measured by the Scale of Prodromal Symptoms (SOPS) total score when compared to subjects receiving RT training across study time.

Eligibility criteria: Inclusion Criteria:

* Meet Clinical High Risk criteria
* Be of Latino descent
* Speak Spanish as their preferred language

Exclusion Criteria:

* Concomitant medical or neurological illness
* Brain injury with loss of consciousness \> 30 minutes
* Current substance abuse (excluding nicotine)
* IQ \< 80
* High suicidal risk

Primary outcomes:
measure: Neurocognition (Global Cognitive Index z score)
timeFrame: 3 and 6 months post-baseline
Secondary outcomes:
measure: Functional capacity (UPSA/UPSA-A)
timeFrame: 3 and 6 month post-baseline
Other outcomes:
measure: Self-reported functioning (SLoF)
timeFrame: 3 and 6 month post-baseline
measure: Clinical symptom severity (SOPS total)
timeFrame: 3 and 6 month post-baseline
Locations:
city: La Jolla
country: United States
facility: University of California San Diego
state: California
city: Mexico City
country: Mexico
facility: Instituto Nacional de Neurología y Neurocirugía
Study officials:
affiliation: University of California, San Diego
name: Kristin Cadenhead, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01249807: Taiwanese People's Willingness to Participate in Cancer Screening: Colon, Oral Cavity, Breast, and Cervical Cancer Screening
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy
Keywords: Cancer Screening
health service utilization model
quality of health life
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2010-11-30
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: Patients patients' families Community people

Brief summary: Cancer Screening is necessary for promoting cancer prevention in the area of public health. The Department of Health, Executive Yuan of the Republic of China has expanded and included colon cancer screening, oral cavity cancer screening, breast cancer screening, and cervical cancer screening in national-wide preventive healthcare services. However, most of the Taiwanese do not have the concepts of what cancer screening is and regular participation of cancer screening. This will easily cause their neglect of quality of personal healthcare and habits of cancer screening. Recently, in order to reach the national goal of cancer prevention, the parallel methods, multi-promotion for reinforcing concepts and free cancer screening, have been utilized to cultivate Taiwanese people's active participation of cancer screening. Therefore, this study will use health service utilization model to investigate Taiwanese people's concepts of cancer-related knowledge and the major causes of low participation of cancer screening.

In order to investigate Taiwanese people's health service utilization model and quality of health life, this study first review the related regulations and screening rates of cancer prevention, including cancers of colon, oral cavity, breast, and cervical, in Taiwan. In addition, the structured questionnaire will be conducted to collect, investigate, and analyze the relationship between the willingness of participating the aforementioned cancer screening and personal characteristics, quality of health life, medical history, and concepts of cancer, etc. It is expected that the results of this study will provide accurate and effective promotions of cancer screening to medical institutions and medical affairs to reinforce the concepts of participation for raising the rates of cancer screening; furthermore, to awaken Taiwanese people's crucial awareness of early treatment improves the chances of recovery on cancer.


Eligibility criteria: Inclusion Criteria:

Cases who are willing to answer the questionnaire

Exclusion Criteria:

Cases who are not willing to answer the questionnaire

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University Hospital
Study officials:
References:
Clinical trial NCT06328907: Multifunctional Nutrition Tube on Social Condition and Experience in Cerebralvascular Accident
Official title: Multifunctional Nutrition Tube on Social Condition and Experience in Cerebralvascular Accident: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Stroke
Lead sponsor: Chao Phya Abhaibhubejhr Hospital
Sponsor class: OTHER_GOV
First posted: 2024-03-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this clinical trial is to compare the psychological condition and experience of ischemic stroke patients who receive enteral nutrition support through either Intermittent Oro-esophageal Tube or Nasogastric Tube. Patients will be randomly assigned to either an observation group or a control group, with both groups receiving routine rehabilitation treatment. The observation group will receive enteral nutrition support through Intermittent Oro-esophageal Tube, while the control group will receive it through Nasogastric Tube. Researchers will then compare the Social Condition and experience of the two groups.

Detailed description: The study will last 15 days for each participant. The goal of this clinical trial is to compare the differences on Psychological Condition and Experience in ischemic stroke patients using Intermittent Oro-esophageal Tube and Nasogastric Tube. Patients will be randomly divided into an observation group and a control group, all receiving routine rehabilitation treatment. On this basis, the observation group will use Intermittent Oro esophageal Tube for enteral nutrition support, while the control group will use Nasogastric Tube. Researchers will compare Social Condition and Experience of two groups.

Eligibility criteria: Inclusion Criteria:

* Age\>18 years.
* Meeting the diagnostic criteria for ischemic stroke .
* Dysphagia confirmed by video fluoroscopic Swallowing Study.
* Clear consciousness.
* Stable vital signs.

Exclusion Criteria:

* Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, etc.
* Complicated with severe liver and kidney failure, tumors, or hematological disorders.
* Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
* Pregnant or nursing females.

Primary outcomes:
measure: Swallowing-Quality of Life questionnaire
timeFrame: day 1 and day 15
Secondary outcomes:
measure: The Reintegration to Normal Living Index
timeFrame: day 1 and day 15
measure: Functional Oral Intake Scale
timeFrame: day 1 and day 15
measure: Patient Health Questionnaire-9
timeFrame: day 1 and day 15
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02877407: Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse
Official title: A Randomized Controlled Study of Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Uterovaginal Prolapse
Hysteropexy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2016-08-24
Enrollment: 146
Sex: FEMALE
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * objective: aimed to compare laparoscopic/robot-assisted hysteropexy with vaginal hysterectomy for uterine prolapse
* prospective randomized clinical trial
* patient

  1. 60yrs or more women and
  2. POP-Q stage II with symptom or POP-Q III, IV regardless of symptom
* number of patient: 146
* randomize: laparoscopic/robot-assisted hysteropexy vs. hysterectomy
* follow up: postoperative 1 year
* primary endpoint: recurrence rate

  1. recurrence of uterovaginal prolapse POP-Q stage II-IV
  2. recurrence of associated symptom
* secondary endpoint

  1. postoperative 1 year QOL, degree of satisfaction evaluation
  2. operative time, estimated blood loss
  3. hospitalization period, postoperative pain, return to normal activity


Eligibility criteria: Inclusion Criteria:

* POP-Q stage II with symptom or POP-Q III, IV regardless of symptom

Exclusion Criteria:

* abnormal uterine bleeding
* significantly enlarged fibroid uterus
* postmenopausal uterine bleeding
* endometrial pathology
* on tamexifen
* concomitant medical problems precluding general anesthesia or surgery
* damaged agreement ability

Primary outcomes:
measure: recurrence rate (%)
timeFrame: postoperative 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National Univesity Bundang Hospital
state: Kyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Dong Hun Suh, associate professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02139007: Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
Official title: Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Osteoporosis
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2014-05-15
Enrollment: 27
Sex: FEMALE
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot study evaluating the recruitment strategies for sites and patients, data collection instruments, follow-up procedures, administrative processes, and the proposed management strategy for the future large scale national trial.


Eligibility criteria: Inclusion Criteria:

1.Females 65+

2.3+ years of alendronate (Fosamax/Binosto) use

3. Valid social security number

Exclusion Criteria:

1. History of any other metabolic bone condition, such as Paget Disease of Bone
2. Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.
3. Has significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)?
4. HIV positive
5. Involved in a conflicting (investigational drug) clinical trial

Primary outcomes:
measure: All Study Sites--Length of Contracting Procedures
timeFrame: Length of time Between Clinical Site Recruitment and Contract Execution
measure: All Study Sites--Length of Time to Site IRB Approval
timeFrame: Length of time to site IRB approval
measure: All Study Sites-Length of Time to 1st Participant Enrolled
timeFrame: Length of time t for sites to recruit/enroll 1st participant
Secondary outcomes:
measure: Clinical Fracture Rate
timeFrame: Baseline to 6 months following enrollment
measure: Atypical Femoral Fracture
timeFrame: Baseline to 6 months following enrollment
measure: Osteonecrosis of the Jaw
timeFrame: Baseline to 6 months following enrollment
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
affiliation: University of Alabama at Birmingham
name: Kenneth G Saag, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03991507: PCOS (Polycystic Ovarian Syndrome) Patients
Official title: Prospective Cohort Study for PCOS Patients in Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Health Related
Lead sponsor: The First Affiliated Hospital of Zhengzhou University
Sponsor class: OTHER
First posted: 2019-06-19
Enrollment: 10000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: PCOS patients diagnosed with The Rotterdam diagnostic criteria.

Brief summary: The Prospective Cohort Study for PCOS Patients was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, China.

Detailed description: Polycystic ovary syndrome (PCOS) affects 8-13% of women. It is a multifaceted condition characterized by chronic anovulation and excess ovarian activity.

Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. The current project plans to recruit PCOS participants in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for PCOS prognosis.

Eligibility criteria: Inclusion Criteria:

* PCOS patients diagnosed with The Rotterdam diagnostic criteria.

Exclusion Criteria:

-

Primary outcomes:
measure: Level of serum FSH (Follicle stimulating hormone)
timeFrame: From date of inclusion, assessed by each 12 month, up to 40 years
measure: Level of serum LH (Luteinizing hormone)
timeFrame: From date of inclusion, assessed by each 12 month, up to 40 years
measure: Level of T (Testosterone)
timeFrame: From date of inclusion, assessed by each 12 month, up to 40 years
Secondary outcomes:
measure: Body Weight
timeFrame: From date of inclusion, assessed by each 12 month, up to 40 years
measure: Height
timeFrame: From date of inclusion, assessed by each 12 month, up to 40 years
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University
state: Henan
Study officials:
References:
Clinical trial NCT06317207: Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy
Official title: Reoperation for Ipsilateral Local Recurrence Following Prior Nephron-sparing Surgery: Innovative Surgical Insights From a High-volume Urological Center
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Cell Carcinoma
Robotic Surgical Procedures
Lead sponsor: The First Affiliated Hospital of Anhui Medical University
Sponsor class: OTHER
First posted: 2024-03-19
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We collected the patients who underwent reoperation for locally rRCC after pNSS in our institution from 2013 to 2023.

Brief summary: To evaluate the safety of reoperation in patients with renal tumors who have ipsilateral tumor recurrence after nephron-sparing partial nephrectomy.


Eligibility criteria: Inclusion Criteria:

1. ipsilateral local rRCC (any recurrence in the ipsilateral kidney and retroperitoneum)

Exclusion Criteria:

1. With distant metastasis;
2. Lacking essential sugery information.

Primary outcomes:
measure: Operation time
timeFrame: 1 week
Secondary outcomes:
measure: Estimated blood loss
timeFrame: 1 week
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02244307: Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade
Official title: Evolution of Patients Suffering From Benign Prostatic Hyperplasia (BPH) Treated With Alpha-adrenergic Blockade (JOSEPHINE)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostatic Hyperplasia
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-19
Enrollment: 4561
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with BPH for whom alpha-blockade treatement is indicated recruited at general practitioners

Brief summary: The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers. The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.


Eligibility criteria: Inclusion Criteria:

* Any patient with BPH for whom alpha-blocker treatment is indicated
* Patients who are already on class-1 alpha-blockers can only participate in the study if all information required is known and/or available

Exclusion Criteria:

* Patient's follow-up not possible
* Patients participating in another study
* History of BPH surgery
* Prostate cancer

Primary outcomes:
measure: Assessment of prognosis factors for having recourse to prostatic surgery
timeFrame: up to 2 years
Secondary outcomes:
measure: Time form alpha-adrenergic blockade treatment initiation to surgery
timeFrame: up to 2 years
measure: Occurrence of concomitant BPH diseases
timeFrame: up to 2 years
measure: Total International Prostate Symptom Score (IPSS)
timeFrame: up to 2 years
measure: Percentage of patients with ongoing BPH treatment
timeFrame: up to 2 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03307707: New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder
Official title: Heart Failure and Early Stage Chronic Kidney Disease -Mineral Bone Disorder : the Importance of the New Biomarkers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Disease, Chronic
Heart Failure
Keywords: FGF23
klotho
Mineral Bone Disorder
Lead sponsor: University of Monastir
Sponsor class: OTHER
First posted: 2017-10-12
Enrollment: 111
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: subjects who visited the emmergency departement or the nephrology departement , meeting the criteria inclusion and have given a written consent .

Brief summary: the objective of this study is to :

-Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker of HF in patients with CKD-MBD.

Detailed description: The disorders of mineral metabolism and bone disease are common complications in CKD patients and they are associated with increased morbidity and mortality.

Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness contributing to left ventricular hypertrophy and its pathophysiology involves newly discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho.

The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate early in in the advancement of CKD stage to attain levels in CKD stage 5D.

But we still have few knoweledges if these markers can have some drawbacks for predicting CVD in early stage CKD.

Eligibility criteria: Inclusion Criteria:

* Early CKD stage
* Heart failure

Exclusion Criteria:

* Infections
* cancer
* corticoid therapy
* renal replacement therapy
* Advanced CKD stage

Primary outcomes:
measure: Fibroblast Growth Factor 23 (FGF23)
timeFrame: completed data base (after 4 months)
measure: Alpha Klotho
timeFrame: completed data base (after 4 months)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Research Laboratory (LR12SP18) University of Monastir Tunisia, Tunisia and Research Unit (UR17ES29) Faculty of Pharmacy , Monastir
name: Lamti Feten, PhD student
role: STUDY_CHAIR
References: